Clinical Trial Update: Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing safety and immunogenicity of synthetic DNA vaccines encoding NP-GT8 and interleukin-12, with or without a TLR-agonist-adjuvante…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Synthetic DNA vaccines encoding NP-GT8 and interleukin-12 (DNA vaccine encoding NP-GT8 and interleukin-12)
• TLR-agonist-adjuvanted HIV Env Trimer 4571 boost (TLR-agonist-adjuvanted HIV Env trimer (4571) booster)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2025-11-14